Icu Medical Inc/DeICUI

NasdaqHealthcareSurgical & Medical Instruments & Apparatus

Price (close)

$166.02

Market cap

$4.2B

P/E

138.0x

Revenue (TTM)

$2.2B

Net income

$30.1M

Dividend yield

—

1-year total return

40.4%

Net margin

1.4%

Revenue growth

-9.0%

Debt / equity

0.57x

What Icu Medical Inc/De does.

First person pronouns used in this Annual Report on Form 10-K, such as “we,” “us,” and “our,” refer to ICU Medical, Inc. (“ICU”) and its subsidiaries unless context requires otherwise.

ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions offered on behalf of our joint venture; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.

Headquartered in San Clemente, California, ICU was founded in 1984. Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. Since our inception we have grown organically and through acquisitions.

Revenue and profit, by fiscal year.

Fiscal year	2020	2021	2022	2023	2024	2025
Revenue	$1.3B	$1.3B	$2.3B	$2.3B	$2.4B	$2.2B
Net income	$86.9M	$103.1M	-$74.3M	-$29.7M	-$117.7M	$732,000
Free cash flow	$130.7M	$199.0M	-$152.4M	$82.3M	$124.7M	$91.8M

More on ICUI.

Figures from Icu Medical Inc/De's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.